Replacement of activated vitamin D has been the cornerstone of therapy for secondary hyperparathyroidism (SHPT). Recent findings from several large observational studies have suggested that the benefits of vitamin D receptor activators (VDRA) may extend beyond the traditional parathyroid hormone (PTH)-lowering effect, and could result in direct cardiovascular and metabolic benefits. The advent of several new analogs of the activated vitamin D molecule has widened our therapeutic armamentarium, but has also made therapeutic decisions more complicated. Treatment of SHPT has become even more complex with the arrival of the first calcium-sensing receptor (CSR) agonist (cinacalcet hydrochloride) and with the uncovering of novel mechanisms responsible for SHPT. We provide a brief overview of the physiology and pathophysiology of SHPT, with a focus on vitamin D metabolism, and discuss various practical aspects of VDRA therapy and its reported association with survival in recent observational studies. A detailed discussion of the available agents is aimed at providing the practicing physician with a clear understanding of the advantages or disadvantages of the individual medications. A number of open questions are also analyzed, including the present and future roles of CSR agonists and 25(OH) vitamin D replacement. Disorders of mineral and bone metabolism are common in patients with chronic kidney disease (CKD) 1 and have been implicated as a novel risk factor in the high mortality seen in this patient population. 2, 3 These encompass not only conditions related to the traditionally defined renal osteodystrophy, including secondary hyperparathyroidism (SHPT), disorders of vitamin D metabolism, hyperphosphatemia, and hypo-and hypercalcemia, but also more recently defined disease states related to vascular calcification. Due to this wide range of complications, the more inclusive term CKD mineral and bone disorder (CKD-MBD) is currently favored. 4 Several of the abnormalities characterizing CKD-MBD have been amenable to therapeutic interventions, and have hence become a cornerstone of our day-to-day management of patients with CKD. One of these is SHPT, which is due in part to the progressive decline in activated vitamin D levels with advancing stages of CKD. 1, 5 Replacement of activated vitamin D has thus become the main strategy in the treatment of SHPT. The introduction of a number of analogs of the activated vitamin D molecule, together known as vitamin D receptor activators (VDRA), has broadened our therapeutic armamentarium, 6, 7 but has also made decisions about which drug to use more complicated. We examine the rationale for the therapeutic use of activated vitamin D, provide an overview of the effects of various available analogs of activated vitamin D, and summarize the available scientific evidence supporting the use of them, alone or in combination with other therapeutic agents such as calcium-sensing receptor (CSR) agonists or 25(OH) vitamin D. In particular, we review the recent observational data on the association of VDRA and survival in CKD and expand our discussion on interpretation of such associative data in the setting of clinical practice and current and anticipated treatment guidelines.
More recently, fibroblast growth factor 23 has emerged as a new regulator that plays an important role in CKD-MBD. 13 Fibroblast growth factor 23, like PTH, has phosphaturic properties, but, unlike PTH, it inhibits 1-a-hydroxylation and hence leads to lower levels of activated vitamin D and further stimulation of PTH production. 13 Additionally, fibroblast growth factor 23 may have a direct stimulatory effect on the parathyroid glands, hence further contributing to SHPT. 14 As kidney function declines in patients with CKD, their PTH levels become increasingly higher, mirrored by a progressive decline in activated vitamin D levels. 1 It is unclear to what extent these different pathophysiological mechanisms (intrinsic loss of enzymatic activity vs. suppression by fibroblast growth factor 23) contribute to the lower 1-ahydroxylase activity, but the net effect is a progressive decline in activated vitamin D levels with advancing stages of CKD. 1 Administration of synthetic activated vitamin D to replace physiological levels of this hormone thus appears to be a plausible strategy to treat SHPT. The application of activated vitamin D in physiological doses often fails to correct SHPT, in part due to decreased expression of the vitamin D receptor in the parathyroid gland. 8 This can be overcome by the administration of higher doses of activated (1,25(OH) 2 ) vitamin D, but such pharmacological doses are more likely to induce side effects. Most relevant of these undesirable side effects are hypercalcemia and hyperphosphatemia, 15 which have themselves been associated with higher mortality in patients on dialysis. 2, 3 To circumvent such side effects, new agents have been developed that showed a more selective effect toward suppressing PTH production, with a lesser effect on intestinal and bone absorption of calcium and phosphorus. 16, 17 These novel analogs of activated vitamin D (paricalcitol and doxercalciferol in the United States and alpha-calcidol and maxacalcitol outside the United States) appeared to have less effects on the vitamin D receptors in the gastrointestinal tract and bone, thus mitigating calcium and phosphorus absorption and allowing a wider therapeutic margin. Nevertheless, the concept of VDRA selectivity and its utility in clinical practice has been a matter of ongoing debate. 18 
THE CASE FOR VDRA: BENEFITS BEYOND LOWERING OF PTH?
While the only current indication for the use of activated vitamin D and its analogs in patients with CKD is the treatment of SHPT, the impact of lowering PTH levels may extend beyond the skeletal system and includes potential cardiovascular and metabolic benefits. 2, 3, 19 This has prompted a number of large observational studies examining outcomes associated with the use of activated vitamin D therapy in patients on maintenance dialysis, 3, [20] [21] [22] [23] [24] and in patients with CKD not yet on dialysis 25 (Table 1 ). These studies incorporated data from a very large number of patients and consistently showed that patients treated with any kind of VDRA experienced significantly lower all-cause and cardiovascular mortality rates compared with patients not receiving any treatment.
The most obvious explanation for the observed benefits could be the effects induced by the lowering of PTH level ( Figure 1 ). Elevated PTH has been shown to induce a number of cardiovascular (myocardial fibrosis, left-ventricular hypertrophy, decreased myocardial contractility, increased vascular, and valvular calcification, decreased vasodilatation), 26, 27 metabolic (decreased insulin sensitivity and disorders of lipid metabolism), [28] [29] [30] hematological (bone marrow fibrosis and decreased erythropoiesis), 31, 32 and immunological 33 abnormalities. Treatment of SHPT could thus improve or reverse a number of these abnormalities, potentially translating into a better survival.
On the other hand, the broad benefits observed in the studies shown in Table 1 suggest that the impact of VDRA reaches beyond lowering of PTH levels. Subgroup analyses in these studies indicated that virtually all patients benefited 25 520 Calcitriol vs no treatment from activated vitamin D therapy, including patients with lower PTH or higher calcium or phosphorus levels. 20, 23 Furthermore, vitamin D deficiency was associated with higher all-cause and cardiovascular mortality in a large cohort of hemodialysis patients, 34 and lower 1,25(OH) 2 vitamin D levels have been associated with worsened coronary calcification, 35 also suggesting a PTH-independent link between vitamin D and survival. The vitamin D receptor is ubiquitous, and its stimulation has been shown to have wide-ranging effects. 6 Some of the many physiological effects of vitamin D receptor activation could explain how the administration of activated vitamin D could directly impact on the cardiovascular system: by regressing cardiac hypertrophy, 36 by decreasing the activation of the renin-angiotensin system, 37 by inhibiting the production of proteins implicated in arterial calcification, [38] [39] [40] by stimulating the production of proteins that are inhibitors of arterial calcification, 38, 41 by inhibiting the production of cytokines that are involved in calcification and atheroma formation 42, 43 and stimulating the production of cytokines that are inhibiting it, 44, 45 and by preventing thrombosis 46 (Figure 1 ). Non-cardiovascular effects related to stimulation of vitamin D receptor include increased production of cathelicidine 47 anticancer effects. 48 Such effects could explain the broad benefit seen with activated vitamin D therapy in observational studies, independent of the abnormalities of CKD-MBD. All the above putative mechanisms of action form a plausible explanation for why the administration of VDRA was associated with lower mortality in observational studies. Since the vast majority of the studies elucidating the mechanism of action of VDR activation come from non-human experimental studies, their extrapolation to clinical practice will have to wait for proof by randomized controlled trials (RCTs).
VDRA AND SURVIVAL IN CKD: ASSOCIATION OR CAUSALITY?
Examining therapeutic interventions in observational studies is always subject to confounding bias, no matter how rigorous the statistical adjustments are. Recent examples where the results of observational studies were refuted by RCTs 49-51 serve as a cautionary tale against using observational data as final proof of a beneficial effect. A set of criteria for making the leap from association to causation was systematically presented in the 1965 article of Sir Austin Bradford Hill, 'The Environment and Disease: Association or Causation'. 52 As shown in Table 2 , applying Hill's criteria to the available evidence on activated vitamin D therapy shows that six of the nine criteria appear to be satisfied. One (dose response) is not (although the reason for this could be confounding by the higher PTH levels seen in those receiving higher doses of activated vitamin D 3 ), one needs more research (specificity), and one (experimentation) requires controlled trials. There also are novel epidemiological techniques such as structural nested modeling, marginal structural modeling, propensity-based matching, or instrumental variable analysis that can better account for timevarying confounders and that are sometimes called 'causal models'. [53] [54] [55] [56] Such methodology was applied in the study by Teng et al., 23 the results of which were concordant with the studies' that applied more conventional methodologies. Nevertheless, a conclusive answer could only be provided by an RCT.
WHICH VITAMIN D ANALOG IS THE BEST?
Disorders of CKD-MBD are complex and incorporate conditions such as hyperphosphatemia and disorders in calcium metabolism beside SHPT. Higher phosphorus and calcium levels have been associated with increased mortality in patients on dialysis; 2,3 hyperphosphatemia has also been associated with higher mortality 57, 58 and more progression of kidney disease [58] [59] [60] in patients with earlier stages of CKD. Treatment with the native VDRA calcitriol effectively suppresses SHPT, but can have less salutary effects by inducing hyperphosphatemia and hypercalcemia. This has prompted the development of several activated vitamin D analogs that can suppress PTH production, with a lesser concomitant hypercalcemic and hyperphosphatemic effect. 7, [61] [62] [63] One question that arises is whether the salutary side effect profile of these activated vitamin D analogs translates into superior outcomes compared to patients receiving calcitriol? If the benefit of activated vitamin D therapy is indeed broad ranging and extends to patient groups with hyperphosphatemia and hypercalcemia, 3,23 the favorable side effect r e v i e w profile of the more selective drugs may not be that important.
On the other hand, the activated vitamin D analogs may be different from calcitriol in ways other than their lesser intestinal effects. [64] [65] [66] The activation of the VDR is a complex process that involves recruitment of a multitude of coactivators and corepressors. 67 Differential recruitment of such elements distinguishes the gene activation profile seen with VDR stimulation from paricalcitol and calcitriol, 65 which could translate into significant differences in their clinical effects. Supporting an advantage from activated vitamin D analogs are animal models showing that paricalcitol induced significantly less vascular calcification compared to calcitriol. 68, 69 A more complicated picture is suggested by another experimental model of 5/6 nephrectomized rats, showing that animals treated with paricalcitol displayed significant reductions in endogenously produced activated vitamin D (calcitriol) levels and showed increased perivascular fibrosis, but also a higher density of intramyocardial capillaries. 66 These results suggest that calcitriol and activated vitamin D analogs may differ significantly in their ancillary effects. While some of these ancillary effects (such as the effect on calcium, phosphorus, vascular calcification and capillary density) seem to favor the analogs (or rather specifically paricalcitol), others may be beneficial to calcitriol (such as the more severe perivascular fibrosis seen with paricalcitol treatment). What is unclear from these pre-clinical results is the effect of the various activated vitamin D molecules on clinical outcomes in patients with CKD. Teng et al. 70 examined such outcomes in a historical cohort of 67 399 patients on maintenance hemodialysis, and found that treatment with paricalcitol was associated with a 16% lower all-cause mortality compared to treatment with calcitriol ( Table 3) .
Contrasting the foregoing findings, Tentori et al. 24 compared outcomes in patients receiving paricalcitol, doxercalciferol, and calcitriol in 7731 maintenance hemodialysis patients, and found no differences between the three groups after adjustment for potential confounders. The reason for the discrepant findings of these observational studies is unclear; RCT are needed to settle this issue. Other benefits of activated vitamin D analogs were suggested by studies showing lower hospitalization rates in patients treated with paricalcitol vs calcitriol. 71 This may be one of the reasons why a cost analysis suggested that the use of paricalcitol provided cost-savings compared with calcitriol, in spite of its higher price. 72, 73 Limitations inherent of observational data apply to these studies as well, and short of an RCT their results can also be only viewed as hypothesis-generating.
A different concern arises in patients with CKD who are not yet on dialysis, where progressive loss of kidney function represents an important outcome. Pharmacological doses of calcitriol may hasten loss of kidney function through induction of hypercalciuria or hyperphosphatemia; 60, 74 this effect is not seen with lower doses of calcitriol, 25, 75, 76 which also have been associated with a trend toward slower progression of kidney disease in patients with CKD stages 3 and 4. 25, 76 Hypercalciuria is also a lesser concern with activated vitamin D analogs, 77, 78 of which paricalcitol has also been shown to reduce proteinuria in patients with CKD stages 3 and 4, 79 and to attenuate renal interstitial fibrosis in experimental obstructive nephropathy. 80 For the time being, our clinical practice will have to be directed by what the approved indications of these medications are (treatment of SHPT), and hence the choice of agent (calcitriol vs analog VDRA) will continue to be driven by patient tolerance, individual side effect profiles, and cost considerations. In patients with CKD who are not yet on dialysis, physiological doses of calcitriol may be able to adequately control the less severe SHPT, without deleterious side effects and with a potentially renoprotective effect; 25, 76 if higher doses are necessary, activated vitamin D analogs (especially paricalcitol) may be safer.
The second practical question pertains to the choice of particular activated vitamin D analog. The two agents available in the United States (paricalcitol and doxercalciferol) were approved on the basis of their ability to lower PTH with a more favorable side effect profile compared with that of calcitriol, 77,78,81-86 but they have different pharmacological characteristics. There are currently very few head-to-head comparison studies between these two agents. Paricalcitol may have a more favorable side effect profile in experimental animals, with lower calcium and phosphorus absorption, 61 and lower vascular calcification. 69, 87 Doxercalciferol may hold an advantage due to its longer half-life, leading to more consistent bioavailability. 7 The available clinical studies comparing paricalcitol and doxercalciferol were underpowered and have suboptimal study designs. One study found similar serum calcium and phosphorus levels with equivalent doses of the two agents in a before-after design of 27 dialysis patients. 88 A second study, a 36-h crossover study in 13 dialysis patients, showed comparable PTH suppression with high doses of these two agents, but significantly higher serum phosphorus levels and calcium Â phosphorus products in those receiving doxercalciferol. 89 Regarding survival benefits, the only study comparing the two agents was observational and found no difference in outcomes between patients on maintenance hemodialysis treated with the two drugs. 24 Thus, there is currently insufficient evidence to clearly distinguish one activated vitamin D analog from the other in clinical practice, and decisions about which one to use will be based most likely on individual patient characteristics or practitioner preference. Due to the complexity of VDR activation, it is possible that differences between the various activated vitamin D analogs are substantial and go beyond their immediately obvious effects on serum PTH, calcium, and phosphorus. Betterdesigned and head-to-head conducted clinical comparisons are needed to determine which drug is superior in terms of clinical end points, especially survival.
UNANSWERED QUESTIONS Should all patients receive treatment with activated vitamin D?
Observational studies are unanimous in their findings that patients receiving any kind of activated vitamin D have lower mortality compared with those who do not (Table 1) . 3, [20] [21] [22] [23] [24] [25] This benefit may or may not be related to lowering of PTH, but because treatment of SHPT is the only approved indication for the different VDRA, it is unclear what an optimal regimen would be to maximize patient survival. On the basis of their PTH levels, a significant proportion of patients do not receive treatment with VDRA because of concerns related to over-suppression of PTH levels and adynamic bone disease. 90 Observational studies in patients receiving maintenance dialysis support the current PTH target levels recommended by the K-DOQI guidelines, 91 in that PTH levels below the recommended 150-300 pg ml À1 seem to be associated with poorer survival. 3 Complementing these findings, however, patients with low PTH levels who were treated with VDRA in the same study had lower mortality compared with those who did not. 3 It is possible that the higher mortality that is in general associated with states of lower PTH level (and adynamic bone disease) is the result of confounding by a state of malnutrition and inflammation, [92] [93] [94] in which case treatment with VDRA would not necessarily lead to worsened outcomes, in spite of further lowering of their PTH levels. This question could only be answered satisfactorily by a clinical trial; short of such a trial, the current practice of only administering VDRA therapy for treatment of SHPT has to be favored.
What is the role of 25(OH) vitamin D replacement?
The natural precursor of activated vitamin D (that is, 1,25(OH) 2 ) is 25(OH) vitamin D, and hence a deficiency of the latter can play a role in the low activated vitamin D levels seen in patients with CKD. 95 Low 25(OH) vitamin D levels are very common in patients with CKD, 96 but while activated vitamin D levels appear to decline progressively with worsening kidney function, 25(OH) vitamin D levels do not. 1 This suggests that 1-a-hydroxylation in the kidneys may be a more important determinant of activated vitamin D levels rather than the availability of its precursor. 25(OH) Vitamin D is able to suppress PTH production in vitro by virtue of direct stimulation of the VDR and a slow tissuelevel 1-a-hydroxylation; 97 the low affinity of 25(OH) vitamin D to the VDR is presumably counterbalanced by its higher plasma concentration. Indeed, a small observational study examined the effect of 25(OH) vitamin D (ergocalciferol) replacement on PTH levels in patients with stage 3 and 4 CKD and found this strategy to be somewhat successful only in the subgroup with stage 3 CKD. 98 Similar studies in patients on dialysis have also questioned the effectiveness of 25(OH) vitamin D therapy in achieving suppression of SHPT and resolution of bone histological changes. 99 It is yet unclear what the longer-term outcomes of 25(OH) vitamin D replacement might be. Lower 25(OH) vitamin D levels were associated with significantly higher mortality in an observational study of incident hemodialysis patients, but subsequent treatment with activated vitamin D nullified this association; replacement of 25(OH) vitamin D was not performed and thus its effect could not be analyzed. 34 Studies examining replacement of 25(OH) vitamin D in patients with no kidney disease support a beneficial effect on survival, 100 but the results of these studies cannot be extrapolated to patients with CKD, due to the differences in activated vitamin D levels between these two populations. It is possible that the benefits of 25(OH) vitamin D replacement are partially independent of activated vitamin D, if 25(OH) vitamin D indeed has roles other then being a mere precursor to activated vitamin D. [101] [102] [103] [104] [105] In this case, replacement of both components could be beneficial, but this idea needs to undergo formal testing. Such a combined application may especially be beneficial in patients treated with activated vitamin D analogs, the selectivity of which may prevent them from compensating for abnormalities brought about by 25(OH) vitamin D (and consequently, calcitriol) deficiency. 106 Can CSR agonists circumvent the need for VDRA in CKD?
The advent of CSR agonists has not only added another weapon to our armamentarium against SHPT, but also has made therapeutic decisions more complicated. The only CSR agonist currently available for clinical use is cinacalcet; this agent has been shown to effectively lower PTH levels and to lower the risk of parathyroidectomy, fracture, and cardiovascular hospitalization, along with improvements in selfreported physical function and diminished pain. 107, 108 Patients treated with cinacalcet may develop hypocalcemia, which has been severe in about 5% of dialysis patients enrolled in a clinical trial examining the efficacy and safety of this drug. 108 Although the majority of the hypocalcemic 1360 Kidney International (2008) 73, 1355-1363 r e v i e w episodes seen with cinacalcet therapy are asymptomatic, 108 it is unclear what its long-term consequences are.
While cinacalcet was only approved in the United States for SHPT treatment in patients on dialysis, its use in patients with CKD not yet on dialysis has also been examined. Findings from a clinical trial in this population indicated that patients treated with cinacalcet developed not only hypocalcemia but also significant hyperphosphatemia (possibly related to the diminished phosphaturic effect of the lower PTH levels). 109 Additional concern in patients with earlier stages of CKD is the impact on kidney function of the hypercalciuria that can be expected from an agonist of CSR, this receptor being expressed in the thick ascending limb of the loop of Henle and the distal nephron. 110 These concerns have prompted the recent cessation of the manufacturer's efforts to pursue an indication to treat SHPT with cinacalcet in patients with CKD who are not yet on dialysis in the United States, and to withdraw this indication in Canada.
Finally, still little is known about the impact of cinacalcet on outcomes requiring longer follow-up, such as mortality. A recently initiated clinical trial will be examining this question in hemodialysis patients with SHPT, but its results are probably a few years away. 111 Given all these uncertainties, we believe it is premature to think that CSR agonists can take over the role of VDRAs in the treatment of SHPT. Cinacalcet could be a valuable addition in patients who are not responding adequately to or who are intolerant of higher doses of VDRA.
SUMMARY
Pharmacological administration of activated vitamin D has become the main strategy in the treatment of SHPT. There is a large volume of observational evidence suggesting a broader beneficial effect of such treatments, which could be the result of multiple non-skeletal functions modulated by the vitamin D receptor. The lack of RCTs means that a broadening of the indication of use for activated vitamin D is not yet possible. Due to insufficient clinical data, no single activated vitamin D product can claim to be uniformly superior to the others, although a wider therapeutic window often prompts the use of activated vitamin D analogs in patients requiring higher doses of these medications. Currently available evidence favors individualized treatment decisions when choosing a particular type of activated vitamin D, where detailed knowledge of each of the available agents allows the tailoring of the therapeutic regimen to the individual patients' needs.
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